90961-53-8|Tedisamil|3',7'-Bis(cyclopropylmethyl)spiro(cyclopentane-1,9'-(3,7)diazabicyclo(3.3.1)nonane)|-范德生物科技公司

Tedisamil

NMR下载 COA and HPLC MSDS下载
names：
3',7'-Bis(cyclopropylmethyl)spiro(cyclopentane-1,9'-(3,7)diazabicyclo(3.3.1)nonane)
CAS号：
90961-53-8
MDL Number：
MF(分子式)： C19H32N2 MW(分子量)： 288.48
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	3',7'-Bis(cyclopropylmethyl)spiro(cyclopentane-1,9'-(3,7)diazabicyclo(3.3.1)nonane)
英文别名	Tedisamil; Pulzium; Tedisamil; Tedisamilum;
CAS号	90961-53-8
SMILES	C1(C23CCCC2)CN(CC4CC4)CC3CN(CC5CC5)C1
Inchi	InChI=1S/C19H32N2/c1-2-8-19(7-1)17-11-20(9-15-3-4-15)12-18(19)14-21(13-17)10-16-5-6-16/h15-18H,1-14H2
InchiKey	CTIRHWCPXYGDGF-UHFFFAOYSA-N
分子式 Formula	C19H32N2
分子量 Molecular Weight	288.48
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Tedisamil(CAS:90961-53-8):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Tedisamil is a blocker of K+ currents in cardiac tissues, exerts bradycardic effects and has shown clinical efficacy in angina pectoris. It is an antiarrhythmic drug with predominantly class III activity.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Démolis JL, Martel C, Funck-Brentano C, Sachse A, Weimann HJ, Jaillon P. Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. Br J Clin Pharmacol. 1997 Oct;44(4):403-9. PubMed PMID: 9354317; PubMed Central PMCID: PMC2042860.

[2]Hohnloser SH, Dorian P, Straub M, Beckmann K, Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol. 2004 Jul 7;44(1):99-104. PubMed PMID: 15234416.

[3] van Haarst AD, Dijkmans AC, Weimann HJ, Kemme MJ, Bosch JJ, Schoemaker RC, Cohen AF, Burggraaf J. Clinically important interaction between tedisamil and verapamil. J Clin Pharmacol. 2009 May;49(5):560-7. doi: 10.1177/0091270009332812. Epub 2009 Mar 19. PubMed PMID: 19299533.

[4] Mitrovic V, Miskovic A, Strau M, Thormann J, Pitschner H, Hamm C. Hemodynamic, antiischemic, and neurohumoral effects of tedisamil and atenolol in patients with coronary artery disease. Cardiovasc Drugs Ther. 2000 Oct;14(5):511-21. PubMed PMID: 11101199.

[5] Barrett TD, Hennan JK, Fischbach PS, O'Neill BP, Driscoll EM Jr, Lucchesi BR. Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence. Br J Pharmacol. 2001 Apr;132(7):1493-500. PubMed PMID: 11264243; PubMed Central PMCID: PMC1572702.

6: Doggrell SA, Nand V. Effects of tedisamil on cardiovascular tissues isolated from normo- and hypertensive rats. J Cardiovasc Pharmacol Ther. 2001 Jul;6(3):261-72. PubMed PMID: 11584333.7: Church J, McLarnon JG. Tedisamil blocks BK-type Ca(2+)-dependent K(+) channels and modulates action potentials in rat hippocampal neurons. Neurosci Lett. 2002 Feb 15;319(2):79-82. PubMed PMID: 11825675.8: Fischbach PS, Barrett TD, Goyal R, Tran BC, Syed ZA, Hennan JK, Lucchesi BR. Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models. J Cardiovasc Electrophysiol. 2001 Oct;12(10):1138-44. PubMed PMID: 11699522.9: Freestone B, Lip GY. Tedisamil: a new novel antiarrhythmic. Expert Opin Investig Drugs. 2004 Feb;13(2):151-60. PubMed PMID: 14996649.10: Beatch GN, Abraham S, MacLeod BA, Yoshida NR, Walker MJ. Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K+ current blocker. Br J Pharmacol. 1991 Jan;102(1):13-8. PubMed PMID: 2043919; PubMed Central PMCID: PMC1917915.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开